Cells

 

 

 

<p>Case discussion with Drs. Tom Hensing of in Chicago &amp; David Jackman in Boston, discussing practical issues around molecular marker testing &amp; recommended treatments for first line &amp; maintenance therapy for a patient with advanced squamous cell NSCLC.</p>  

<p>Case discussion with Drs. Tom Hensing of in Chicago &amp; David Jackman in Boston, discussing practical issues around molecular marker testing &amp; recommended treatments for first line &amp; maintenance therapy for a patient with advanced squamous cell NSCLC.</p>  

Dr Stanzani explains that fungal cells are very similar to human cells, and that drugs which are toxic to fungals cells may have the same effect on human cells. Mortality in invasive aspergillosis depends largely on the timing of the intervention, timely diagnosis and the state of the patient’s defences – treatment is much more effective when people have an intact immune system.  

MeetTheProfessors.com – 62yo w/squamous cell carc. 3-4cm above anal verge; rcvd neoadj rad. therapy & 5-FU/mitomycin; tumor was not visible/palpable after chemo but seen on ultrasound; AP resection revealed submucosal disease, with 5/19 positive nodes  

MeetTheProfessors.com – 49-year-old w/right lower lobe mass & history of poorly diff. squamous cell oropharynx carcinoma; pneumonectomy; pathology found 4-cm adenosquamous cell carcinoma w/neg. margins, 3 pos. lymph nodes; now receiving doce/cis chemo  

A poster made to understand the entire pathway from ingestion of a pathogen, activation of a T-Cell, and the targets of a range of immunosuppressive drugs  

My "questions and answer" sheets I use to revise. These sheets are much like the look, cover, copy sheets I used as a young child learning to spell and, although a primitive idea, they help me ensure I learn the topic.  

This animation shows a simplified version of the macrophage's role in the initiation of atherosclerosis. In an atherosclerotic-prone blood vessel, macrophages invade the subendothelial space. Oxidised Low-Density Lipoproteins (oxLDL) present within the vessel wall will bind to scavenger receptors on the macrophage's surface, such as CD36. This will activate the macrophage, and it will phagocytose the oxLDL. As this process continues, the macrophage increases in size and forms a Foam Cell, which is too large to pass between the endothelial cells back into the lumen. Therefore, the foam cells remain in the subendothelial space and are the main cells present within an atherosclerotic plaque. *** Done for Student Selected Component (SSC), University of Aberdeen. Year 2. 2011. Made in Adobe Photoshop CS2 and Adobe Imageready.  

This animation shows a simplified version of the macrophage's role in the initiation of atherosclerosis. In an atherosclerotic-prone blood vessel, macrophages invade the subendothelial space. Oxidised Low-Density Lipoproteins (oxLDL) present within the vessel wall will bind to scavenger receptors on the macrophage's surface, such as CD36. This will activate the macrophage, and it will phagocytose the oxLDL. As this process continues, the macrophage increases in size and forms a Foam Cell, which is too large to pass between the endothelial cells back into the lumen. Therefore, the foam cells remain in the subendothelial space and are the main cells present within an atherosclerotic plaque. *** Done for Student Selected Component (SSC), University of Aberdeen. Year 2. 2011. Made in Adobe Photoshop CS2 and Adobe Imageready.  

Revision notes from First Year at The University of Manchester Faculty of Life Sciences.  

This diagram was created to summarise my dissertation. It shows numerous methods of immune evasion methods of a cancer cell. I did a lot of research around this subject and never found a diagram that brought this number of methods together, so created one.  

This is a diagram I created to summarise the immune response, complete with friendly, loveable cartoon immune cells designed in an attempt to make what can be a very complicated and confusing subject seem a little less threatening. The students I taught the subject to loved the "cute" summary format and found immunology to be a much more approachable revision topic as a result! Since this image has been so popular with all you lovely people, I have also written a comprehensive article on the immune response - complete with lots of illustrations - which is available here on Geeky Medics: http://geekymedics.com/2014/07/02/immune-response/ Enjoy and good luck!  

Uveal melanoma is a rare but very aggressive malignancy: independently of the currently available therapies, 50 % of patients will develop metastasis and median survival time of these patients is only less than 8 months.  

Some notes on recent studies discussing the relationship between stem cell & some autoimmune diseases. Please leave a comment!  

Struggling with Pathology? Why not join Howard Reisner, co-author of the bestselling Rubin’s Pathology, and Essentials of Rubin's Pathology, about Cell Injury and death. In it, he covers a variety of essential topics. For more information, or to purchase your copy of one of Dr Reisner’s books, visit [www.lww.co.uk](http://lww.co.uk). Save 15% (and get free P&P) on this, and a whole host of other [LWW titles](http://lww.co.uk) when you use the code MEDUCATION when you check out!  

• Type 1 diabetes – a primary deficiency of insulin, β- cell destruction leads to failure of insulin secretion. May be due to an autoimmune reaction against th…  

Scientists at King's have demonstrated the ability to deliver a dried live vaccine to the skin without a traditional needle, and shown for the first time that this technique is powerful enough to enable specialised immune cells in the skin to kick-start the immunising properties of the vaccine. Dr Linda Klavinskis from the Peter Gorer Department of Immunobiology at King's explains the research behind the new technique and its wider potential. Read more about this technique on the King's College London website: http://www.kcl.ac.uk/newsevents/news/newsrecords/2013/02-Feb/Injection-free-vaccination-technique.aspx.